Scientists have found a surprising new way to make certain cancer drugs work dramatically better – by helping them get inside ...

Isomorphic Labs raised $600 million in its first external funding round, led by Thrive Capital with participation from GV and Alphabet, according to the Financial Times. The AI-first drug design and ...

AlphaFold 3, the improved version of the model used by Isomorphic Labs’ drug design engine, debuted last May. It can predict the shape of not only proteins but also DNA, RNA and other biological ...

Presently departmental laboratories are devoted toward drug design, synthesis, and characterization. Additionally there is also a strong effort placed in protein receptor characterization and protein ...

Researchers in pharma and beyond have historically glommed onto a limited number of disease targets, limiting innovation. AI ...

Isomorphic Labs, the AI drug-discovery platform that was spun out of Google's DeepMind in 2021, has raised external capital ...

Ethan Grimes, BS, and Paul Morgan, MD, conduct rational drug design at the newly launched AI Small Molecule Drug Discovery Center at the Icahn School of Medicine at Mount Sinai. As part of Mount Sinai ...

Isomorphic will use the windfall to fund development of its next-generation artificial intelligence drug design model, the company announced in a March 31 release. The AI biotech is also looking ...

A novel antiviral targeting the SARS-CoV-2 PLpro protease shows strong efficacy in a mouse model, preventing lung pathology and reducing brain dysfunction. The study provides proof-of-principle ...

The subsidiary of Google parent Alphabet plans to use its first round of external funding to boost its ...

Drug discovery has always been a complex and multi-faceted process that requires the integration of various disciplines such as biology, chemistry, and computer science. Today Artificial Intelligence ...